Physician profile
Robin L Smith
NPI 1659325355
$4,559.38
in general payments reported to CMS, 2019-2025
40 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $62.39 · 2021: $274 · 2022: $786 · 2023: $1,019 · 2024: $901 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,283.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.03 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $475.75 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Abbott Laboratories | $459.87 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $438.88 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $298.03 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals Lp | $258.44 | 2023-2025 | Airsupra, Breztri |
| Gilead Sciences, INC. | $219.06 | 2019-2025 | Descovy |
| Novo Nordisk INC | $216.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $166.16 | 2020-2025 | |
| Exact Sciences Corporation | $164.13 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $163.91 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.62 | 2022-2025 | Xifaxan, Trulance |
| Myriad Women'S Health, INC. | $74.06 | 2023 | Myrisk |
| Sumitomo Pharma America, INC. | $69.34 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.09 | 2019-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.